| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | 62,0 k € | |||||||||||
| Gross margin | 654,1 k € | -5.8% | 694,7 k € | -10.9% | 780,1 k € | +4.7% | 745,0 k € | +8.3% | 688,0 k € | -2.8% | 707,7 k € | +61.4% | 438,5 k € | -5.4% | 463,5 k € | -3.5% | 480,1 k € | -4.6% | 503,5 k € | — | ||
| EBITDA | 23,3 k € | +1.6% | 22,9 k € | -6.3% | 24,4 k € | -57.8% | 57,9 k € | +12.2% | 51,6 k € | +8.4% | 47,6 k € | +579.0% | -9,9 k € | -1110.6% | 982,9 € | -85.1% | 6,6 k € | -11.5% | 7,4 k € | +144.8% | -16,6 k € | |
| Operating profit | 20,4 k € | -0.1% | 20,4 k € | -6.4% | 21,8 k € | -61.2% | 56,1 k € | +14.2% | 49,2 k € | +7.4% | 45,8 k € | +520.4% | -10,9 k € | -656.9% | -1,4 k € | -138.8% | 3,7 k € | -18.7% | 4,6 k € | +126.7% | -17,1 k € | |
| Profit/loss | 8,2 k € | +39.8% | 5,9 k € | +843.7% | -789,3 € | -101.9% | 42,1 k € | +56.0% | 27,0 k € | -20.6% | 34,0 k € | +332.4% | -14,6 k € | -11.2% | -13,1 k € | -3740.2% | 361,0 € | -77.8% | 1,6 k € | +109.5% | -17,1 k € | |
| Equity | 223,4 k € | +3.8% | 215,2 k € | +2.8% | 209,3 k € | -0.4% | 210,1 k € | +25.0% | 168,1 k € | +19.1% | 141,1 k € | +31.7% | 107,1 k € | -12.0% | 121,8 k € | -9.7% | 134,9 k € | +0.3% | 134,5 k € | +1.2% | 132,9 k € | |
| Total assets | 492,7 k € | -6.5% | 526,9 k € | -5.2% | 556,1 k € | -44.0% | 992,9 k € | -35.1% | 1,5 M € | +34.9% | 1,1 M € | +297.3% | 285,4 k € | +16.9% | 244,1 k € | -29.7% | 347,1 k € | -0.7% | 349,4 k € | +86.9% | 187,0 k € | |
| Cash | 103,4 k € | -47.5% | 197,0 k € | -5.6% | 208,6 k € | -12.6% | 238,8 k € | -68.1% | 747,8 k € | +39.5% | 536,2 k € | +580.1% | 78,8 k € | +62.4% | 48,6 k € | -59.0% | 118,4 k € | +90.8% | 62,1 k € | -40.8% | 104,8 k € | |
| Debts | 252,2 k € | -13.5% | 291,4 k € | -11.3% | 328,5 k € | -57.2% | 767,3 k € | -43.0% | 1,3 M € | +36.9% | 982,5 k € | +451.3% | 178,2 k € | +58.6% | 112,4 k € | -36.8% | 177,8 k € | -7.6% | 192,4 k € | +317.3% | 46,1 k € | |
| Staff | 3,9 | 4,3 | 5,7 | 6 | 5,6 | 4,8 | 4,3 | 4 | 4 | 4 | 0,8 | |||||||||||
Private limited company · Bruxelles · incorporated on 05/08/2015 · 3,9 ETP
Private limited company profitable and well capitalised. Cash position declining (-47.5%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
PHARMA MAR is a Private limited company incorporated in 2015. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Bruxelles. It employs on average 3,9 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette